Evidence map›Paper›PMID 33336320›Full record

ArticlePharmacoEconomics2021

Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment.

Seamus Kent, Edward Burn, Dalia Dawoud, Pall Jonsson, Jens Torup Østby, Nigel Hughes, Peter Rijnbeek, Jacoline C Bouvy

Abstract read
In one paragraph

Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Evaluating Frailty Index Integrity: Insights from an International Network Study.medRxiv : the preprint server for health sciences · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Seamus KentNational Institute for Health and Care Excellence, London, United Kingdom.ORCID 0000-0001-7298-3163
Edward BurnCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.
Dalia DawoudNational Institute for Health and Care Excellence, London, United Kingdom.
Pall JonssonNational Institute for Health and Care Excellence, London, United Kingdom.
Jens Torup ØstbyPfizer Inc, Oslo, Norway.
Nigel HughesJanssen Research and Development, Beerse, Belgium.
Peter RijnbeekDepartment of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jacoline C BouvyNational Institute for Health and Care Excellence, London, United Kingdom. Jacoline.Bouvy@nice.org.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these problems. The open-source Observational and Medical Outcomes Partnerships (OMOP) common data model standardises the structure, format, and terminologies of otherwise disparate datasets, enabling the execution of common analytical code across a federated data network in which only code and aggregate results are shared. While common data models are increasingly used in regulatory decision making, relatively little attention has been given to their use in health technology assessment (HTA). We show that the common data model has the potential to facilitate access to relevant data, enable multidatabase studies to enhance statistical power and transfer results across populations and settings to meet the needs of local HTA decision makers, and validate findings. The use of open-source and standardised analytics improves transparency and reduces coding errors, thereby increasing confidence in the results. Further engagement from the HTA community is required to inform the appropriate standards for mapping data to the common data model and to design tools that can support evidence generation and decision making.

Indexed as

Technology Assessment, BiomedicalCost-Benefit AnalysisHumans

Identifiers

PMID33336320
PMCPMC7746423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.